Eurocine Vaccines AB Reports Earnings Results for the Full Year Ended June 30, 2022

Eurocine Vaccines AB is a Sweden-based clinical-stage company, which develops nasal vaccines. The Company develops vaccines up to proof of concept (clinical phase I/II) and license to partners for further development and commercialization. Also, the Company offers license partners vaccine adjuvant technologies, which are a key element of the nasal vaccines, for development in various indications. For these purposes the Company’s uses its clinically validated technology Endocine. In addition, the Company’s primary project is the nasal quadrivalent influenza vaccine Immunos FLU that aims for children from six month. The Company cooperates with both academic researchers and contract businesses and owns all income generated in these collaborations.